Pfizer and Dynamiker Biotechnology Sign Strategic Partnership to Advance Precision Diagnosis and Treatment of Invasive Fungal Diseases

The incidence of invasive fungal diseases (IFD) continues to rise worldwide. With complex diagnostic pathways and high treatment difficulty, IFD has become a major global public health challenge. According to data released by the World Health Organization in April 2025, more than 6.5 million people develop IFD each year, with related deaths reaching 3.8 million. The absence of typical clinical manifestations and the limited sensitivity of traditional diagnostic methods make early diagnosis and precise treatment of IFD persistently difficult in clinical practice. In recent years, China’s health authorities have issued a series of policies emphasizing the need to strengthen laboratory diagnostic capabilities for fungal diseases and to promote the rational use of antifungal drugs, in response to the growing threats of fungal resistance and diagnostic-treatment bottlenecks.

As a global leader in anti-infectives, Pfizer brings advanced therapies and comprehensive solutions to the field of IFD management. The company has long been committed to addressing the challenges of fungal resistance and improving clinical care in China. Leveraging its deep expertise and robust anti-infective portfolio, Pfizer not only provides clinicians with effective therapeutic options but also actively supports nationwide professional education and academic exchange. By collaborating with leading Chinese experts, promoting standardized diagnostic and treatment practices, and advancing rational antifungal stewardship in hospitals, Pfizer continues to contribute to the overall improvement of fungal disease prevention and control—demonstrating its responsibility as an industry leader.

Dynamiker Biotechnology (Tianjin) Co., Ltd. is a national high-tech enterprise dedicated to the research, development, manufacturing, and commercialization of innovative in vitro diagnostic products for invasive fungal diseases and other pathogenic microorganisms. As a global leader in combined fungal testing and precision diagnostics, Dynamiker Biotechnology has driven technological innovation and standard-setting within China’s fungal diagnostics industry. Its integrated testing solutions provide critical support for the early, rapid, and accurate diagnosis of IFD, significantly improving patient experience and clinical outcomes.

United by a shared vision to build a seamless pathway from precision diagnosis to precision treatment—and to more effectively prevent and control invasive fungal diseases—the two parties signed a strategic cooperation agreement on December 1, 2025. The signing ceremony was attended by Mr. Xu Decai, General Manager of Pfizer’s Hospital Acute Care Business Unit; Ms. Zhang Huihui, Head of Innovative Markets; Mr. Zhou Zeqi, Chairman of Dynamiker Biotechnology; and Ms. Wang He, Deputy General Manager. Under this partnership, Pfizer and Dynamiker Biotechnology will work together to advance precision diagnosis and treatment of IFD, promote the adoption of advanced diagnostic solutions in high-risk departments such as hematology, and enable earlier detection and more accurate therapy—contributing to the enhancement of fungal disease prevention and treatment capabilities nationwide.